Compounded Semaglutide After the FDA Crackdown: 2026 Status

Background

How We Got Here

Beginning in 2022, ongoing shortages of FDA-approved semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) triggered the FDA's drug shortage provisions. Under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies could legally produce versions of these drugs while official shortage status held.

That created a several-billion-dollar parallel market of compounded GLP-1s offered through telehealth platforms — typically $150–$400/month, well below branded list prices.

Novo Nordisk and Eli Lilly successfully petitioned the FDA to remove their drugs from the shortage list as supply caught up: tirzepatide in late 2024 and semaglutide in early 2025.

Where things stand

What's Actually Legal in Mid-2026

With semaglutide and tirzepatide off the shortage list, the broad 503A/503B compounding exemptions for these drugs ended. The FDA issued enforcement deadlines and grace periods in 2025 that have now expired.

Compounding remains legal under specific 503A circumstances — most notably when a documented clinical reason exists that the FDA-approved product cannot be used (for example, a documented allergy to an excipient). Mass-market 'cheaper version' compounding is not within that exception.

FDA warning letters, state board actions against pharmacies, and federal action against telehealth platforms continuing to market compounded GLP-1s for cost reasons alone have continued through 2025–2026. Several major compounding pharmacies and telehealth operators have entered consent decrees, ceased operations, or pivoted to other peptides.

[VERIFY current FDA enforcement status at publish — this area is moving.]

Risks

Why the Risk Profile Was Higher Than Marketed

FDA-approved semaglutide and tirzepatide are manufactured in controlled facilities with extensive sterility, identity, and potency requirements. Compounded versions varied widely in source ingredient quality, purity, sterility, and dosing accuracy.

FDA testing has documented compounded semaglutide products containing the wrong salt form (semaglutide sodium), products with incorrect dosing, products with bacterial contamination, and products mislabeled as compounded that were in fact unregulated peptide from non-pharmacy sources.

Reported adverse events from compounded GLP-1s include dosing errors leading to hospitalization, injection site infections, and severe hypoglycemia from inaccurate concentration.

What to do if you were on compounded

If You Were Taking Compounded Semaglutide or Tirzepatide

Coordinate transition with a physician. Options include:

• ·Transition to FDA-approved branded therapy. Manufacturer self-pay direct pricing (Novo Care, Lilly Direct) has narrowed the price gap that originally drove patients to compounded products. [VERIFY current direct-pay pricing.]
• ·Reassess candidacy and goals. Patients near their target weight may transition to a maintenance dose or to a structured taper.
• ·Avoid switching pharmacies just to find a cheaper compounded source. Pharmacies still offering 'compounded GLP-1' at telehealth prices in mid-2026 are operating in a high enforcement risk zone, with product quality concerns proportional to the regulatory laxity.

Honest framing

The Honest Framing for Patients

The compounded GLP-1 market existed because access and affordability of branded drugs lagged demand. The clinical case for FDA-approved product has not changed; the price gap has narrowed; and the regulatory tolerance for mass-market compounded versions has effectively ended.

Telehealth platforms continuing to aggressively market compounded GLP-1s in mid-2026 are increasingly an outlier and a regulatory risk for both pharmacy and prescriber. Patient-facing risk is principally product quality.